New gel could outperform standard therapy for kidney disease
Disease control
Recruiting now
This Phase 3 trial is testing a new gel called SNP-ACTH (1-39) against the standard drug rituximab in 148 adults with primary membranous nephropathy, a rare kidney condition. The goal is to see if the gel can better reduce protein in the urine and protect kidney function over 24 …
Phase: PHASE3 • Sponsor: Cerium Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC